AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 19, 2021
29864_dirs_2021-02-19_9b2f6a4b-8d02-43ed-ad30-e5f1e55d1966.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-17
Reporting Person: Silva Paul M (SVP & Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-17 | Common Stock | F | 2740 | $211.75 | Disposed | 21123 | Direct |
| 2021-02-18 | Common Stock | S | 584 | $210.05 | Disposed | 20539 | Direct |
| 2021-02-18 | Common Stock | S | 2343 | $211.82 | Disposed | 18196 | Direct |
| 2021-02-18 | Common Stock | S | 1368 | $212.62 | Disposed | 16828 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 169 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.05 (range $209.59 to $210.37).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.82 (range $211.15 to $212.14).
F5: Open market sales reported on this line occurred at a weighted average price of $212.62 (range $212.15 to $213.14).